JP2004123785A - N-alkanoylated hyaluronic acid or its salt, and its production method - Google Patents
N-alkanoylated hyaluronic acid or its salt, and its production method Download PDFInfo
- Publication number
- JP2004123785A JP2004123785A JP2002285769A JP2002285769A JP2004123785A JP 2004123785 A JP2004123785 A JP 2004123785A JP 2002285769 A JP2002285769 A JP 2002285769A JP 2002285769 A JP2002285769 A JP 2002285769A JP 2004123785 A JP2004123785 A JP 2004123785A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- hyaluronic acid
- alkanoylated
- cationic compound
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、ｎ−アルカノイル化ヒアルロン酸もしくはその塩およびその製造法に関する。さらに詳しくは、疎水部位と親水部位を併せ持ち、医療品、食品、化粧品分野などの新しい素材として有用なｎ−アルカノイル化ヒアルロン酸もしくはその塩およびその製造法に関する
【０００２】
【従来の技術】
ヒアルロン酸はＮ−アセチルーＤ−グルコサミンとＤ−グルクロン酸が交互に結合してできた直鎖状の高分子多糖であり、多数の遊離カルボキシル基と多数の遊離ヒドロキシル基を有するために水に対する親和性に富み、任意の量の水に溶けて高粘度の水溶液を形成する。この遊離カルボキシル基と遊離ヒドロキシル基を封鎖する事により物性の異なるヒアルロン酸を入手することが期待される。そのため、医療品、食品、化粧品分野などに使用することを目的として、ヒアルロン酸またはその塩（以下、「ヒアルロン酸（塩）」と記述することがある）の化学修飾が行われている（例えば、特許文献１，２参照。）。しかしながら、従来の何れの反応も水分子の存在する系での反応であり、ヒアルロン酸（塩）の化学修飾に適用しうる有機反応が制限されていた。このため、医療品、食品、化粧品分野などの新しい素材となる疎水部位と親水部位を併せ持つ新しいタイプのヒアルロン酸（塩）の製造は非常に困難であった。
【０００３】
【特許文献１】
特開平７−３０９９０２号公報
【特許文献２】
特開平８−５３５０１号公報
【０００４】
【発明が解決しようとする課題】
本発明者らは、医療品、食品、化粧品分野などの新しい素材として有用な、疎水部位と親水部位を併せ持つ新しいタイプのヒアルロン酸（塩）について鋭意研究した。その結果、ヒアルロン酸（塩）とカチオン性化合物との複合体を非水系溶媒に溶解し、次いで該複合体をｎ−アルカノイル基を有する酸ハロゲン化物と反応させることにより、疎水域と親水域を併せ持つ新しいタイプのヒアルロン酸（塩）が得られることを見出し、この知見に基づいて本発明を完成した。
以上の記述から明らかなように、本発明の目的は、医療品、食品、化粧品分野などの新しい素材として有用な、疎水部位と親水部位を併せ持つ新しいタイプのヒアルロン酸（塩）、特に、非水系での製造であるため発熱物質、抗原性物質などの混入が少なく、さらに体内で代謝されるため特に医薬分野で、例えば手術時等の保湿剤、潤滑剤、創傷被覆剤、さらにはＤＤＳ（ドラッグデリバリーシステム）材料として利用できるヒアルロン酸（塩）およびその製造法を提供することである。
【０００５】
【課題を解決するための手段】
本発明は、以下の（１）〜（１０）で示される。
（１）下記一般式（１）で表されるｎ−アルカノイル化ヒアルロン酸もしくはその塩。
【０００６】
（２）ｎ−アルカノイル基が、下記一般式（２）で表されるｎ−アルカノイル基である前記（１）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩。
ＣＨ３−（ＣＨ２）ｍ−ＣＯ− （２）
（式中、ｍは４〜１０の整数を表す。）。
【０００７】
（３）カチオン性化合物が第４級アンモニウム塩である前記（１）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩。
【０００８】
（４）第４級アンモニウム塩がジステアリルジメチルアンモニウム塩である前記（３）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩。
【０００９】
（５）ヒアルロン酸もしくはその塩とカチオン性化合物との複合体を非水系溶媒中でハロゲン化ｎ−アルカノイルと反応させることを特徴とする下記一般式（３）で表されるｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法。
【００１０】
（６）ハロゲン化ｎ−アルカノイルが、下記一般式（４）で表されるハロゲン化ｎ−アルカノイルである前記（５）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法。
ＣＨ３−（ＣＨ２）ｍ−ＣＯ−Ａ （４）
（式中、ｍは３〜１５の整数を表し、Ａはハロゲンを表す。）。
【００１１】
（７）ハロゲン化ｎ−アルカノイルが、下記一般式（５）で表されるハロゲン化ｎ−アルカノイルである前記（５）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法。
ＣＨ３−（ＣＨ２）ｍ−ＣＯ−Ａ （５）
（式中、ｍは４〜１０の整数であり、Ａはハロゲンを表す。）。
【００１２】
（８）非水系溶媒がＤＭＦ，エタノール、メタノール、アセトン、クロロホルム、トルエン、塩化メチレンまたはヘプタンから選ばれた１種以上の溶媒である前記（５）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造方法。
【００１３】
（９）カチオン性化合物が第４級アンモニウム塩である前記（５）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法。
【００１４】
（１０）第４級アンモニウム塩がジステアリルジメチルアンモニウム塩である前記（９）記載のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法。
【００１５】
【発明の実施の形態】
本発明に使用するヒアルロン酸（塩）は特に限定されるものではなく、鶏の鶏冠など各種動物組織由来であっても、ヒアルロン酸（塩）の生産能を有する微生物由来であってもよいが、本発明に使用するヒアルロン酸（塩）は微生物由来であることが好ましい。ヒアルロン酸生産能を有する微生物としては、例えばストレプトコッカス・ピオゲネス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｙｏｇｅｎｅｓ）、ストレプトコッカス・エクイシミリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｅｑｕｉｓｉｍｉｌｉｓ）、ストレプトコッカス・エクイ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｅｑｕｉ）、ストレプトコッカス・デイスガラクテイエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｄｙｓｇａｌａｃｔｉａｅ）、ストレプトコッカス・ズーエピデミカス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｚｏｏｅｐｉｄｅｍｉｃｕｓ）などを挙げることができる。
【００１６】
微生物による生産は、例えば、１リットル当たりブドウ糖２０〜３０ｇ、酵母エキス５ｇ、リン酸１カリウム３ｇ、リン酸２カリウム２ｇ、チオ硫酸ナトリウム０．１ｇ、硫酸マグネシュウム７水塩０．１ｇ、亜硫酸ナトリウム０．０２ｇ、塩化コバルト０．０１ｇ、塩化マンガン０，０１ｇ、泡消剤５ｇを含む培地に予め準備しておいた種菌を添加し、ｐＨ６．０〜８．５、好ましくは７．０、培養温度２５℃〜４０℃、好ましくは３０℃〜３５℃で１〜３日間振とう培養もしくは通気培養し、ヒアルロン酸（塩）を該培養液中に生成蓄積させ、該培養液を遠心分離もしくはろ過して菌体を除去した後、ろ過液を限外ろ過もしくは透析することによって低分子量物質を除去し、低分子量物質を除去したろ過液に塩化ナトリウムを溶解後、水溶性有機溶剤を添加してヒアルロン酸ナトリウムを沈殿させ、該沈殿を遠心分離回収後、真空乾燥する方法を挙げることができる。また、和光純薬製、ナカライテスク製、東京化成製、生化学工業製、シグマ製など市販の試薬グレードのヒアルロン酸（塩）を使用しても特に差し支えない。
【００１７】
また、本発明において原料として使用するヒアルロン酸（塩）はＨＰＬＣ法により測定される平均分子量が、少なくとも５０００から１５０万のものが好ましい。該ＨＰＬＣによる平均分子量の測定には、多糖類の分子量測定に適する任意のカラムを用いることができるが、例えばＳｈｏｄｅｘ Ｉｏｎｐａｋ ＫＳ８０６およびＩｏｎｐａｋ ＫＳ−Ｇ等のカラムを用いることが好ましい。この場合、溶出液としては０．２ｍｏｌ／Ｌ の塩化ナトリウム水溶液を用い、流速１．０ｍｌ／分で流し、ヒアルロン酸（塩）の検出は２０６ｎｍで行うことができる。該平均分子量は極限粘度で求めた分子量既知のヒアルロン酸ナトリウムで作製した検量線を用いて計算により求めることができる。
【００１８】
陽イオンとしては、アルカリ金属イオン、カリウムイオン，ナトリウムイオンなどを挙げることができ、本発明においてはナトリウムイオンが好ましい。
【００１９】
本発明において用いるカチオン性化合物は、具体的には第４級アンモニウム塩、アミノ基を２個以上有するアミノ酸、ペプチド、ポリアミノ酸の塩、およびアミノ基を有する糖質の塩などを挙げることができ、好ましくは第４級アンモニウム塩である。
【００２０】
第４級アンモニウム塩としては、アルキル基のうちの少なくとも１個が炭素数８個以上からなるものが好ましい。具体的には、ジステアリルジメチルアンモニウムクロライド（Ｄｉｓｔｅａｒｙｌｄｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、ジオレイルジメチルアンモニウムクロライド（Ｄｉｏｌｅｙｌｄｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、セチルピリジニウムクロライド（Ｃｅｔｙｌｐｙｒｉｄｉｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、セチルトリメチルアンモニウムクロライド（Ｃｅｔｙｌｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、セチルトリメチルアンモニウムブロミド（Ｃｅｔｙｌｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、ジテトラデシルジメチルアンモニウムブロマイド（Ｄｉｔｅｔｒａｄｅｃｙｌｄｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、ジドデシルジメチルアンモニウムブロミド（Ｄｉｄｏｄｅｃｙｌｄｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、ジデシルジメチルアンモニウム ブロミド（Ｄｉｄｅｃｙｌｄｉｍｅｔｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、オクタデシルトリメチルアンモニウムクロライド（Ｏｃｔａｄｅｃｙｌｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、ノルマルオクタデシルトリメチルアンモニウムブロミド（ｎ−Ｏｃｔａｄｅｃｙｌｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、トリドデシルメチルアンモニウムクロライド（Ｔｒｉｄｏｄｅｃｙｌｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、トリオクチルメチルアンモニウムブロミド（Ｔｒｉｏｃｔｙｌｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｂｒｏｍｉｄｅ）、ジオクタノイルＬ−アルファーフォスファチジルコリン（Ｄｉｏｃｔａｎｏｙｌ Ｌ−α−Ｐｈｏｓｐｈａｔｉｄｙｌｃｈｏｌｉｎｅ）、ジラウロイル、Ｌ−アルファーフォスファチジルコリン（Ｄｉｌａｕｒｏｙｌ Ｌ−α−Ｐｈｏｓｐｈａｔｉｄｙｌｃｈｏｌｉｎｅ）、ジパルミトイル Ｄ，Ｌ−アルファーフォスファチジルコリン（Ｄｉｐａｌｍｉｔｏｙｌ Ｄ，Ｌ−α−Ｐｈｏｓｐｈａｔｉｄｙｌｃｈｏｌｉｎｅ）、１，２−ジミリストイル−３−トリメチルアンモニウムプロパン（１，２−Ｄｉｍｙｒｉｓｔｏｙｌ−３−Ｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｐｒｏｐａｎｅ）、１，２―ジオレオイル−３−トリメチルアンモニウムプロパン（１，２−Ｄｉｏｌｅｏｙｌ−３−Ｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｐｒｏｐａｎｅ）、１，２−ジパルミトイル−３−トリメチルアンモニウムプロパン（１，２−Ｄｉｐａｌｍｉｔｏｙｌ−３−Ｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｐｒｏｐａｎｅ）、１，２−ジステアロイル−３−トリメチルアンモニウムプロパン（１，２−Ｄｉｓｔｅａｒｏｙｌ−３−Ｔｒｉｍｅｔｈｙｌａｍｍｏｎｉｕｍ Ｐｒｏｐａｎｅ）、ベンザルコニウムクロライド（Ｂｅｎｚａｌｋｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）、ベンゼトニウムクロライド（Ｂｅｎｚｅｔｈｏｎｉｕｍ Ｃｈｌｏｒｉｄｅ）などを挙げることができる。
【００２１】
ヒアルロン酸（塩）とカチオン性化合物との複合体とはヒアルロン酸のアニオン性部位（カルボキシル基）とカチオン性化合物とがイオン的に結合したものを言い、その調製法の一例を以下に示す。
【００２２】
＜ヒアルロン酸（塩）とカチオン性化合物との複合体の調製法＞
（Ａ） ヒアルロン酸（塩）を蒸留水またはこれに相当する純水に０．０１〜１０重量％の濃度、好ましくは０．０５〜１重量％の濃度になるように溶解する。なお、本発明において、蒸留水に相当する純水とは、例えば、連続イオン交換（Ｅｌｅｃｔｒｉｃ Ｄｅｉｏｎｉｚａｔｉｏｎ）および逆浸透（Ｒｅｖｅｒｓｅ Ｏｓｍｏｓｉｓ）等により精製した水を意味する。
（Ｂ） 一方、ヒアルロン酸（塩）と複合体を形成させるカチオン性化合物、好ましくは第４級アンモニウム塩を蒸留水または純水に添加し、均一に分散させる。
【００２３】
（Ｂ）で調製したカチオン性化合物の水溶液中のカチオン基と、（Ａ）で調製したヒアルロン酸（塩）の水溶液中のカルボキシル基とのモル比が、０．５〜５：１、好ましくは０．７〜１．５：１、例えば１：１になるように２つの水溶液を混合する。
【００２４】
なお、混合する際の温度は室温でも良いが、好ましくは使用するカチオン性化合物のゲル−液晶転移温度以上に両液を加温して行う。
【００２５】
混合により発生した水不溶物は通常化学実験で使用する分離法、例えば遠心分離、吸引ろ過、加圧ろ過等の方法で混合液より回収する。回収した水不溶物は、当該カチオン性化合物のゲル−液晶転移温度以上に加温した蒸留水または純水にて洗浄した後、乾燥に供する。乾燥は、通常化学実験で使用する乾燥手段、例えば常圧乾燥、真空乾燥、凍結乾燥等により行うことができる。
【００２６】
また、本発明において使用しうる非水系溶媒は、例えば、ＤＭＦ，エタノール、メタノール、アセトン、クロロホルム、塩化メチレン、トルエン、ヘプタン、プロピレングリコール、ポリエチレングリコール、ＤＭＳＯ、ＴＨＦ等、またはこれらの２種以上の混合溶媒が包含される。ＤＭＦ，エタノール、メタノール、アセトン、クロロホルム、塩化メチレン、トルエンもしくはヘプタン、またはこれらの混合溶媒が好ましい。
【００２７】
非水系溶媒に溶解させるヒアルロン酸（塩）とカチオン性化合物との複合体の濃度は、特に限定するものではないが、１〜１０００ｍｍｏｌ／Ｌの範囲であることが好ましい。
【００２８】
該複合体の非水系溶媒への溶解後に行うＯ−アシル化反応（ｎ−アルカノイル化反応）としては、ピリジンなど塩基性溶剤の存在下、ハロゲン化ｎ−アルカノイルを用いるＯ−アシル化法（Ｓｃｈｏｔｔｅｎ−Ｂａｕｍａｎｎ法）などを挙げることができる。ここで、ハロゲン化ｎ−アルカノイルとしては具体的には、ｎ−ブチリルクロライド、ｎ−ヘキサノイルクロライド、ｎ−オクタノイルクロライド、ｎ−デカノイルクロライド、ｎ−ドデカノイルクロライド、ｎ−ステアロイルクロライド等を挙げる事ができ、Ｃ４〜Ｃ１８、好ましくはＣ５〜Ｃ１７、より好ましくはＣ６〜Ｃ１２のハロゲン化ｎ−アルカノイルである。
【００２９】
例えば、Ｏ−アシル化反応がｎ−ドデカノイル化、即ちｎ−ドデカノイル化ヒアルロン酸（塩）の製造の場合は、上述のように得られたヒアルロン酸（塩）のカチオン性化合物複合体を窒素雰囲気下、ＤＭＦに溶解し、ピリジン、ｎ−ドデカノイルクロライドを加え攪拌し、反応液に酢酸ナトリウム飽和エタノールを加え、析出した沈殿をアセトン／水（９／１）で洗浄後、真空乾燥し、ｎ−ドデカノイル化ヒアルロン酸（塩）を得ることができる。
【００３０】
本発明のｎ−アルカノイル化ヒアルロン酸（塩）の用途は、特に限定されるものではないが、医薬品、食品、化粧品分野などに用いられる各種材料として使用可能である。特に本発明のｎ−アルカノイル化ヒアルロン酸（塩）は、非水系での製造であるため発熱物質、抗原性物質などの混入が少なく、さらに体内で代謝されるため特に医薬分野で、例えば手術時等の保湿剤、潤滑剤、創傷被覆剤、さらにはＤＤＳ（ドラッグデリバリーシステム）材料として用いることが可能である。中でもその子宮内における分解速度が、人体（子宮）内のバイオリズムと高い相関性を示すことが期待されていることから、例えば子宮内膜症治療薬を担持する子宮内もしくは膣内埋植用製剤のデバイスとして極めて有効である。
【００３１】
【実施例】
以下、実施例をもって本発明を詳細に説明する。
各種のｎ−アルカノイル化ヒアルロン酸（塩）の製造例を以下に示す。
実施例１
１．ｎ−ブチリル化ヒアルロン酸（塩）の製造
１−１． ヒアルロン酸とジステアリルジメチルアンモニウムクロライド錯体の作製
ヒアルロン酸ナトリウム（チッソ ＣＨＡ、極限粘度より求めた平均分子量５万、以下、「ＣＨＡ」と記載する）１．８ｇを純水３００ｍｌに溶解するとともに、ジステアリルジメチルアンモニウムクロライド（以下、ＤＳＣと略する）２．４７ｇを５６０ｍｌの純水にケン濁させた。両液を４５℃に加温後攪拌しながら混合し、５分間攪拌を続けた。発生した錯体を遠心分離（５０００ｒｐｍ、室温）にて回収し、４５℃の温水にて洗浄した。洗浄終了後、一夜凍結乾燥し、その後、５０℃で一夜真空乾燥し、ヒアルロン酸とジステアリルジメチルアンモニウムクロライド錯体（以下ＣＨＡ−ＤＳＣと略する）を得た。収量３．３ｇ、収率８５％。
【００３２】
１−２．ｎ−ブチリル化ヒアルロン酸の合成
得られたＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、ＤＭＦ３０ｍｌに攪拌溶解させ、目的のＤＳに必要な量のｎ−ブチリルクロライド、ピリジンを加え６０℃、２時間攪拌した。反応終了後、酢酸ナトリウム飽和エタノール溶液（６０ ｍｌ）を加え、ゲルを析出させると共にＤＳＣを除去した。これをアセトン／水＝９：１の溶液で５回洗浄後、６０℃で真空乾燥し、白色固体のｎ−ブチリル化ヒアルロン酸を得た。
【００３３】
実施例２
ｎ−ヘキサノイル化ヒアルロン酸の合成
実施例１の１−１．に準拠して得たＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、ＤＭＦ３０ｍｌに攪拌溶解させ、目的のＤＳに必要な量のｎ−ヘキサノイルクロライド、ピリジンを加え６０℃、２時間攪拌した。反応終了後、酢酸ナトリウム飽和エタノール溶液（６０ ｍｌ）を加え、ゲルを析出させると共にＤＳＣを除去した。これをアセトン／水＝９：１の溶液で５回洗浄後、６０℃真空乾燥し白色固体のｎ−ヘキサノイル化ヒアルロン酸を得た。
【００３４】
実施例３
ｎ−オクタノイル化ヒアルロン酸の合成
実施例１の１−１．に準拠して得たＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、ＤＭＦ３０ｍｌに攪拌溶解させ、ｎ−オクタノイルクロライド１６．３ｍｇ、ピリジン３０ｍｌを加え６０℃、２時間攪拌した。反応終了後、酢酸ナトリウム飽和エタノール溶液（６０ ｍｌ）を加え、ゲルを析出させると共にＤＳＣを除去した。これをアセトン／水＝９：１の溶液で５回洗浄後、６０℃真空乾燥し白色固体のｎ−オクタノイル化ヒアルロン酸を得た。
【００３５】
実施例４
ｎ−デカノイル化ヒアルロン酸の合成
実施例１の１−１．に準拠して得たＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、ＤＭＦ３０ｍｌに攪拌溶解させ、ｎ−デカノイルクロライド１９．１ｍｇ、ピリジン３０ｍｌを加え６０℃、２時間攪拌した。反応終了後、酢酸ナトリウム飽和エタノール溶液（６０ ｍｌ）を加え、ゲルを析出させると共にＤＳＣを除去した。これをアセトン／水＝９：１の溶液で５回洗浄後、６０℃真空乾燥し白色固体のｎ−デカノイル化ヒアルロン酸を得た。
【００３６】
実施例５
ｎ−ドデカノイル化ヒアルロン酸の合成
実施例１の１−１．に準拠して得たＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、ＤＭＦ３０ｍｌに攪拌溶解させ、ｎ−ドデカノイルクロライド２１．９ｍｇ、ピリジン３０ｍｌを加え６０℃、２時間攪拌した。反応終了後、酢酸ナトリウム飽和エタノール溶液（６０ ｍｌ）を加え、ゲルを析出させると共にＤＳＣを除去した。これをアセトン／水＝９：１の溶液で５回洗浄後、６０℃真空乾燥し白色固体のｎ−ドデカノイル化ヒアルロン酸を得た。
【００３７】
実施例６
ｎ−ステアロイル化ヒアルロン酸の合成
実施例１の１−１．に準拠して得たＣＨＡ−ＤＳＣ４６４ｍｇを窒素雰囲気下、６０ ℃でＤＭＦ ３０ ｍｌに溶解し、ピリジン，目的のＤＳに必要な量のステアロイルクロライドを加え、２ ｈｒ攪拌した。反応溶液に酢酸ナトリウム飽和エタノール６０ ｍｌ加え、析出した沈殿をアセトン ／ 水 （９ ／ １ ） で５回洗浄した。これを真空乾燥して白色固体のｎ−ステアロイル化ヒアルロン酸を得た。
なお、ここでいうＤＳとは各反応条件のＨＡ−ＤＳＣと酸ハロゲン化物のモル比で実施した際の理論上のヒアルロン酸二糖単位当たり存在する４個の水酸基へのアルカノイル基の導入割合を表わす。
【００３８】
実施例７
実施例１〜６で得られた各ｎ−アルカノル化ヒアルロン酸の溶解性及びゲル化の評価
各ｎ−アルカノル化ヒアルロン酸５ｍｇを各溶剤１ｍｌに添加、試験管ミキサーで均一にした後、室温で一日放置し、その状態を観察し、その結果を表１〜３に示した。
各表中で溶液特性の表現は以下の状態を意味する
可溶：溶媒に完全に溶解し、ゲル等の形成しない状態
不溶：白色固体のまま溶媒に溶解しない状態
Ｓ−Ｇ（ゾル−ゲル）：溶媒中に細かいゲルを形成した状態
不均一Ｇ（不均一ゲル）：ゲルではあるが均一性を欠くゲル
Ｇ（ゲル）：均一のゲル
【００３９】
表 １ 各種ｎ−アルカノイル化ヒアルロン酸の溶解特性
表 ２ ＤＳが異なるｎ−ブチリル化およびヘキサノイル化ヒアルロン酸の溶解特性
表 ３ ＤＳの異なるｎ−ステアロイル化ヒアルロン酸の溶解特性
【発明の効果】
本発明のｎ−アルカノイル化ヒアルロン酸もしくはその塩は、、疎水域と親水域を併せ持つ新しいタイプのヒアルロン酸（塩）であり、医療品、食品、化粧品分野などの新しい素材として極めて有用である。特に本発明のｎ−アルカノイル化ヒアルロン酸（塩）は、非水系での製造であるため発熱物質、抗原性物質などの混入が少なく、さらに体内で代謝されるため特に医薬分野で、例えば手術時等の保湿剤、潤滑剤、創傷被覆剤、さらにはＤＤＳ（ドラッグデリバリーシステム）材料として利用できる。また、本発明のｎ−アルカノイル化ヒアルロン酸もしくはその塩の製造法は、ヒアルロン酸（塩）とカチオン性化合物との複合体を非水系溶媒に溶解し、次いで該複合体をｎ−アルカノイル基を有する酸ハロゲン化物と反応させることにより、疎水部位と親水部位を併せ持ち、医療品、食品、化粧品分野などの新しい素材として有用なヒアルロン酸（塩）を容易に製造することができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to n-alkanoylated hyaluronic acid or a salt thereof and a method for producing the same. More specifically, the present invention relates to an n-alkanoylated hyaluronic acid or a salt thereof having both a hydrophobic portion and a hydrophilic portion and useful as a new material in the fields of medical products, foods and cosmetics, and a method for producing the same.
[Prior art]
Hyaluronic acid is a linear high molecular polysaccharide formed by alternately bonding N-acetyl-D-glucosamine and D-glucuronic acid, and has many free carboxyl groups and many free hydroxyl groups, and thus has an affinity for water. It is highly soluble and dissolves in any amount of water to form a highly viscous aqueous solution. It is expected that hyaluronic acid having different physical properties will be obtained by blocking the free carboxyl group and free hydroxyl group. Therefore, chemical modification of hyaluronic acid or a salt thereof (hereinafter, sometimes referred to as "hyaluronic acid (salt)") has been performed for the purpose of use in medical products, foods, cosmetics, and the like (for example, , Patent Documents 1 and 2). However, any of the conventional reactions is a reaction in a system in which water molecules are present, and an organic reaction applicable to chemical modification of hyaluronic acid (salt) is limited. For this reason, it has been very difficult to produce a new type of hyaluronic acid (salt) having both a hydrophobic part and a hydrophilic part, which is a new material for medical products, foods, cosmetics and the like.
[0003]
[Patent Document 1]
JP-A-7-309902 [Patent Document 2]
JP-A-8-53501
[Problems to be solved by the invention]
The present inventors have intensively studied a new type of hyaluronic acid (salt) having both a hydrophobic part and a hydrophilic part, which is useful as a new material in the fields of medical products, foods and cosmetics. As a result, the complex of the hyaluronic acid (salt) and the cationic compound is dissolved in a non-aqueous solvent, and then the complex is reacted with an acid halide having an n-alkanoyl group, whereby the hydrophobic region and the hydrophilic region are reduced. The inventors have found that a new type of hyaluronic acid (salt) can be obtained, and based on this finding, have completed the present invention.
As is apparent from the above description, an object of the present invention is to provide a new type of hyaluronic acid (salt) having both a hydrophobic portion and a hydrophilic portion, particularly a non-aqueous system, which is useful as a new material in the fields of medical products, foods and cosmetics. Since it is manufactured in a small amount, there is little contamination with pyrogenic substances, antigenic substances, etc., and it is metabolized in the body. In particular, in the field of medicine, for example, humectants, lubricants, wound dressings, and DDS (drugs) for surgery etc (Delivery system) It is to provide a hyaluronic acid (salt) usable as a material and a method for producing the same.
[0005]
[Means for Solving the Problems]
The present invention is shown by the following (1) to (10).
(1) An n-alkanoylated hyaluronic acid represented by the following general formula (1) or a salt thereof.
[0006]
(2) The n-alkanoylated hyaluronic acid or a salt thereof according to the above (1), wherein the n-alkanoyl group is an n-alkanoyl group represented by the following general formula (2).
CH 3 - (CH 2) m -CO- (2)
(In the formula, m represents an integer of 4 to 10.)
[0007]
(3) The n-alkanoylated hyaluronic acid or a salt thereof according to the above (1), wherein the cationic compound is a quaternary ammonium salt.
[0008]
(4) The n-alkanoylated hyaluronic acid or a salt thereof according to the above (3), wherein the quaternary ammonium salt is distearyl dimethyl ammonium salt.
[0009]
(5) An n-alkanoylated hyaluronic acid represented by the following general formula (3), wherein a complex of hyaluronic acid or a salt thereof and a cationic compound is reacted with an n-alkanoyl halide in a non-aqueous solvent. A method for producing an acid or a salt thereof.
[0010]
(6) The method for producing an n-alkanoylated hyaluronic acid or a salt thereof according to the above (5), wherein the n-alkanoyl halide is an n-alkanoyl halide represented by the following general formula (4).
CH 3 - (CH 2) m -CO-A (4)
(In the formula, m represents an integer of 3 to 15, and A represents halogen.)
[0011]
(7) The method for producing an n-alkanoylated hyaluronic acid or a salt thereof according to the above (5), wherein the n-alkanoyl halide is an n-alkanoyl halide represented by the following general formula (5).
CH 3 - (CH 2) m -CO-A (5)
(In the formula, m is an integer of 4 to 10, and A represents halogen.)
[0012]
(8) The n-alkanoylated hyaluronic acid or a salt thereof according to the above (5), wherein the non-aqueous solvent is one or more solvents selected from DMF, ethanol, methanol, acetone, chloroform, toluene, methylene chloride and heptane. Production method.
[0013]
(9) The method for producing n-alkanoylated hyaluronic acid or a salt thereof according to the above (5), wherein the cationic compound is a quaternary ammonium salt.
[0014]
(10) The method for producing n-alkanoylated hyaluronic acid or a salt thereof according to (9), wherein the quaternary ammonium salt is distearyl dimethyl ammonium salt.
[0015]
BEST MODE FOR CARRYING OUT THE INVENTION
The hyaluronic acid (salt) used in the present invention is not particularly limited, and may be derived from various animal tissues such as chicken cockscomb or derived from a microorganism capable of producing hyaluronic acid (salt). The hyaluronic acid (salt) used in the present invention is preferably derived from a microorganism. The microorganism having a hyaluronic acid-producing ability, for example, Streptococcus pyogenes (Streptococcus pyogenes), Streptococcus equisimilis (Streptococcus equisimilis), Streptococcus equi (Streptococcus equi), Streptococcus Day scan galactosamine Teie (Streptococcus dysgalactiae), Streptococcus zooepidemicus (Streptococcus zooepidemicus).
[0016]
The production by microorganisms is, for example, 20-30 g of glucose per liter, 5 g of yeast extract, 3 g of 1 potassium phosphate, 2 g of 2 potassium phosphate, 0.1 g of sodium thiosulfate, 0.1 g of magnesium sulfate heptahydrate, 0 g of sodium sulfite. To a medium containing 0.02 g, 0.01 g of cobalt chloride, 0.01 g of manganese chloride, and 5 g of an antifoaming agent, a previously prepared inoculum was added, and pH 6.0 to 8.5, preferably 7.0, and culture temperature. Shaking culture or aeration culture at 25 ° C. to 40 ° C., preferably 30 ° C. to 35 ° C. for 1 to 3 days to form and accumulate hyaluronic acid (salt) in the culture solution, and centrifuge or filter the culture solution. After removing the cells by ultrafiltration or dialysis of the filtrate, low molecular weight substances are removed.Sodium chloride is dissolved in the filtrate from which the low molecular weight substances have been removed. Precipitating the sodium hyaluronate with the addition of sexual organic solvent, mention may be made after centrifugation recovered precipitate, a method of vacuum drying. Also, it is possible to use a commercially available reagent grade hyaluronic acid (salt) such as Wako Pure Chemical, Nacalai Tesque, Tokyo Kasei, Seikagaku, or Sigma.
[0017]
The hyaluronic acid (salt) used as a raw material in the present invention preferably has an average molecular weight of at least 5,000 to 1.5 million as measured by HPLC. For the measurement of the average molecular weight by the HPLC, any column suitable for measuring the molecular weight of the polysaccharide can be used. For example, a column such as Shodex Ionpak KS806 and Ionpak KS-G is preferably used. In this case, a 0.2 mol / L aqueous solution of sodium chloride is used as the eluate, the solution is flowed at a flow rate of 1.0 ml / min, and the detection of hyaluronic acid (salt) can be performed at 206 nm. The average molecular weight can be determined by calculation using a calibration curve prepared with sodium hyaluronate having a known molecular weight determined by the intrinsic viscosity.
[0018]
Examples of the cation include an alkali metal ion, a potassium ion, and a sodium ion. In the present invention, a sodium ion is preferable.
[0019]
Specific examples of the cationic compound used in the present invention include a quaternary ammonium salt, an amino acid having two or more amino groups, a peptide, a salt of a polyamino acid, and a saccharide salt having an amino group. And preferably a quaternary ammonium salt.
[0020]
As the quaternary ammonium salt, those in which at least one of the alkyl groups has 8 or more carbon atoms are preferable. Specifically, distearyl dimethyl ammonium chloride (Distearyldimethylammonium Chloride), dioleyl dimethyl ammonium chloride (Dioleyldimethylammonium Chloride), cetylpyridinium chloride (cetylpyridinium Chloride Useful), cetyltrimethylammonium chloride (cetyltrimethylammonium Chloride Useful), cetyltrimethylammonium bromide (cetyltrimethylammonium Bromide) , Ditetradecyldimethylammonium bromide, didodecyldimethylammonium bromide Umuburomido (Didodecyldimethylammonium Bromide), didecyldimethylammonium bromide (Didecyldimetylammonium Bromide), octadecyl trimethyl ammonium chloride (Octadecyltrimethylammonium Chloride), n-octadecyl bromide (n-Octadecyltrimethylammonium Bromide), tridodecylmethylammonium chloride (Tridodecylmethylammonium Chloride), trioctylmethylammonium Ammonium bromide (Trioctylmethylammonium Bromide), dioctanoyl L-al Diphosphanodyl choline (Dioctanoyl L-α-phosphatidylcholine), dilauroyl, L-alpha-phosphatidylcholine (Dilauroyl L-α-Phosphatidylcholine), dipalmitoyl D, L-alpha-dylcholine D, L-alpha-dicholine-D-L-alpha-dicholine-D-L-alpha-dicholine. α-phosphatidylcholine), 1,2-dimyristoyl-3-trimethylammonium propane, 1,2-dioleoyl-3-trimethylammonium propane (1,2-Dioleoyl-3-) Trimethylammonium Propane), 1,2-dipalmitoyl- -Trimethylammonium propane (1,2-Dipalmitoyl-3-Trimethylammonium Propane), 1,2-distearoyl-3-trimethylammonium propane (1,2-Distearoyl-3-Trimethylammonium Propane), Benzalkonium Chloride (Benzalkonium Chloride) , Benzethonium chloride and the like.
[0021]
The complex of hyaluronic acid (salt) and a cationic compound refers to a complex in which an anionic site (carboxyl group) of hyaluronic acid and a cationic compound are ionically bonded, and an example of a preparation method thereof is shown below.
[0022]
<Method for Preparing Complex of Hyaluronic Acid (Salt) and Cationic Compound>
(A) Hyaluronic acid (salt) is dissolved in distilled water or its equivalent pure water to a concentration of 0.01 to 10% by weight, preferably 0.05 to 1% by weight. In addition, in this invention, the pure water equivalent to distilled water means the water refine | purified by continuous ion exchange (Electric Deionization), reverse osmosis (Reverse Osmosis), etc., for example.
(B) On the other hand, a cationic compound capable of forming a complex with hyaluronic acid (salt), preferably a quaternary ammonium salt, is added to distilled water or pure water and uniformly dispersed.
[0023]
The molar ratio of the cationic group in the aqueous solution of the cationic compound prepared in (B) to the carboxyl group in the aqueous solution of hyaluronic acid (salt) prepared in (A) is 0.5 to 5: 1, preferably The two aqueous solutions are mixed so as to be 0.7-1.5: 1, for example 1: 1.
[0024]
In addition, the temperature at the time of mixing may be room temperature, but it is preferable to heat both solutions to a temperature higher than the gel-liquid crystal transition temperature of the cationic compound to be used.
[0025]
The water-insoluble matter generated by the mixing is recovered from the mixture by a separation method usually used in a chemical experiment, for example, a method such as centrifugation, suction filtration, or pressure filtration. The recovered water-insoluble matter is washed with distilled water or pure water heated to a temperature higher than the gel-liquid crystal transition temperature of the cationic compound, and then dried. Drying can be performed by a drying means usually used in a chemical experiment, for example, normal pressure drying, vacuum drying, freeze drying and the like.
[0026]
Non-aqueous solvents that can be used in the present invention include, for example, DMF, ethanol, methanol, acetone, chloroform, methylene chloride, toluene, heptane, propylene glycol, polyethylene glycol, DMSO, THF, and the like, or two or more of these. Mixed solvents are included. DMF, ethanol, methanol, acetone, chloroform, methylene chloride, toluene or heptane, or a mixed solvent thereof is preferred.
[0027]
The concentration of the complex of the hyaluronic acid (salt) and the cationic compound dissolved in the non-aqueous solvent is not particularly limited, but is preferably in the range of 1 to 1000 mmol / L.
[0028]
The O-acylation reaction (n-alkanoylation reaction) performed after dissolving the complex in a non-aqueous solvent includes an O-acylation method (Schotten) using an n-alkanoyl halide in the presence of a basic solvent such as pyridine. -Baumann method) and the like. Here, specific examples of the n-alkanoyl halide include n-butyryl chloride, n-hexanoyl chloride, n-octanoyl chloride, n-decanoyl chloride, n-dodecanoyl chloride, n-stearoyl chloride, and the like. And C 4 -C 18 , preferably C 5 -C 17 , more preferably C 6 -C 12 halogenated n-alkanoyl.
[0029]
For example, when the O-acylation reaction is n-dodecanoylation, that is, in the case of producing n-dodecanoylated hyaluronic acid (salt), the cationic compound complex of hyaluronic acid (salt) obtained as described above is mixed with a nitrogen atmosphere. Under a DMF solution, pyridine and n-dodecanoyl chloride were added and the mixture was stirred. Sodium acetate-saturated ethanol was added to the reaction mixture, and the precipitate was washed with acetone / water (9/1) and dried in vacuo. -Dodecanoylated hyaluronic acid (salt) can be obtained.
[0030]
The use of the n-alkanoylated hyaluronic acid (salt) of the present invention is not particularly limited, but it can be used as various materials used in the fields of pharmaceuticals, foods, cosmetics, and the like. In particular, the n-alkanoylated hyaluronic acid (salt) of the present invention is produced in a non-aqueous system, so that it is less contaminated with pyrogens and antigenic substances, and is further metabolized in the body. It can be used as a humectant, a lubricant, a wound dressing, and a DDS (drug delivery system) material. Above all, since the rate of degradation in the uterus is expected to show a high correlation with the biorhythm in the human body (uterus), for example, the preparation of an intrauterine or vaginal implant preparation carrying a therapeutic agent for endometriosis is recommended. It is extremely effective as a device.
[0031]
【Example】
Hereinafter, the present invention will be described in detail with reference to examples.
Production examples of various n-alkanoylated hyaluronic acids (salts) are shown below.
Example 1
1. Production of n-butyrylated hyaluronic acid (salt) 1-1. Preparation of Hyaluronic Acid and Distearyldimethylammonium Chloride Complex 1.8 g of sodium hyaluronate (nitrogen CHA, average molecular weight determined from intrinsic viscosity: 50,000; hereinafter, referred to as “CHA”) was dissolved in 300 ml of pure water. 2.47 g of stearyl dimethyl ammonium chloride (hereinafter abbreviated as DSC) was suspended in 560 ml of pure water. The two liquids were heated to 45 ° C. and mixed while stirring, and the stirring was continued for 5 minutes. The generated complex was recovered by centrifugation (5000 rpm, room temperature) and washed with hot water at 45 ° C. After the completion of the washing, the mixture was freeze-dried overnight, and then vacuum-dried at 50 ° C. overnight to obtain hyaluronic acid and distearyldimethylammonium chloride complex (hereinafter abbreviated as CHA-DSC). 3.3 g, 85% yield.
[0032]
1-2. Synthesis of n-butyryl hyaluronic acid 464 mg of the obtained CHA-DSC was dissolved in 30 ml of DMF with stirring under a nitrogen atmosphere, and necessary amounts of n-butyryl chloride and pyridine required for DS were added thereto, followed by stirring at 60 ° C for 2 hours. After the completion of the reaction, a saturated ethanol solution of sodium acetate (60 ml) was added to precipitate a gel and to remove DSC. This was washed five times with a solution of acetone / water = 9: 1, and then dried in vacuo at 60 ° C. to obtain a white solid n-butyrylated hyaluronic acid.
[0033]
Example 2
Synthesis of n-hexanoylated hyaluronic acid 1-1 in Example 1 Under a nitrogen atmosphere, 464 mg of CHA-DSC was dissolved in 30 ml of DMF with stirring, and necessary amounts of n-hexanoyl chloride and pyridine for the target DS were added, followed by stirring at 60 ° C. for 2 hours. After completion of the reaction, a saturated ethanol solution of sodium acetate (60 ml) was added to precipitate a gel and to remove DSC. This was washed five times with a solution of acetone / water = 9: 1, and dried in vacuo at 60 ° C. to obtain n-hexanoylated hyaluronic acid as a white solid.
[0034]
Example 3
Synthesis of n-octanoylated hyaluronic acid 1-1 of Example 1 Under a nitrogen atmosphere, 464 mg of CHA-DSC obtained in accordance with the above was dissolved under stirring in 30 ml of DMF, 16.3 mg of n-octanoyl chloride and 30 ml of pyridine were added, and the mixture was stirred at 60 ° C. for 2 hours. After completion of the reaction, a saturated ethanol solution of sodium acetate (60 ml) was added to precipitate a gel and to remove DSC. This was washed five times with a solution of acetone / water = 9: 1, and dried in vacuo at 60 ° C. to obtain n-octanoylated hyaluronic acid as a white solid.
[0035]
Example 4
Synthesis of n-decanoylated hyaluronic acid 1-1 in Example 1 Under a nitrogen atmosphere, 464 mg of CHA-DSC obtained in accordance with the above was dissolved in 30 ml of DMF with stirring, 19.1 mg of n-decanoyl chloride and 30 ml of pyridine were added, and the mixture was stirred at 60 ° C. for 2 hours. After completion of the reaction, a saturated ethanol solution of sodium acetate (60 ml) was added to precipitate a gel and to remove DSC. This was washed 5 times with a solution of acetone / water = 9: 1, and dried in vacuo at 60 ° C. to obtain n-decanoylated hyaluronic acid as a white solid.
[0036]
Example 5
Synthesis of n-dodecanoylated hyaluronic acid 1-1 in Example 1 Under a nitrogen atmosphere, 464 mg of CHA-DSC was dissolved in 30 ml of DMF with stirring, 21.9 mg of n-dodecanoyl chloride and 30 ml of pyridine were added, and the mixture was stirred at 60 ° C. for 2 hours. After the completion of the reaction, a saturated ethanol solution of sodium acetate (60 ml) was added to precipitate a gel and to remove DSC. This was washed five times with a solution of acetone / water = 9: 1, and dried in vacuo at 60 ° C. to obtain n-dodecanoylated hyaluronic acid as a white solid.
[0037]
Example 6
Synthesis of n-stearoylated hyaluronic acid 1-1 of Example 1 464 mg of CHA-DSC obtained in accordance with the above was dissolved in 30 ml of DMF at 60 ° C. under a nitrogen atmosphere, and pyridine and an amount of stearoyl chloride required for a target DS were added thereto, followed by stirring for 2 hours. To the reaction solution, 60 ml of ethanol saturated with sodium acetate was added, and the deposited precipitate was washed five times with acetone / water (9/1). This was vacuum-dried to obtain a white solid n-stearoylated hyaluronic acid.
Here, DS is the ratio of introduction of alkanoyl groups to four hydroxyl groups present per theoretical hyaluronic acid disaccharide unit when the reaction is carried out at a molar ratio of HA-DSC and acid halide under each reaction condition. Express.
[0038]
Example 7
Evaluation of solubility and gelation of each n-alkanolated hyaluronic acid obtained in Examples 1 to 6 5 mg of each n-alkanolated hyaluronic acid was added to 1 ml of each solvent, and after homogenizing with a test tube mixer, at room temperature After one day, the state was observed, and the results are shown in Tables 1 to 3.
In each table, the expression of the solution property means the following states: Soluble: completely dissolved in a solvent and no gel or the like formed Insoluble: white solid not dissolved in a solvent SG (sol-gel) : Fine gel formed in solvent Non-uniform G (heterogeneous gel): Gel that is a gel but lacks uniformity G (gel): Uniform gel
Table 1 Dissolution characteristics of various n-alkanoylated hyaluronic acids
Table 2 Dissolution properties of n-butyrylated and hexanoylated hyaluronic acid with different DS
Table 3 Dissolution characteristics of n-stearoylated hyaluronic acid with different DS
【The invention's effect】
The n-alkanoylated hyaluronic acid of the present invention or a salt thereof is a new type of hyaluronic acid (salt) having both a hydrophobic region and a hydrophilic region, and is extremely useful as a new material in the fields of medical products, foods, cosmetics and the like. In particular, the n-alkanoylated hyaluronic acid (salt) of the present invention is produced in a non-aqueous system, so that it is less contaminated with pyrogens and antigenic substances, and is further metabolized in the body. And the like, and can be used as a humectant, a lubricant, a wound dressing, and a DDS (drug delivery system) material. Further, the method for producing an n-alkanoylated hyaluronic acid or a salt thereof of the present invention comprises dissolving a complex of hyaluronic acid (salt) and a cationic compound in a non-aqueous solvent, and then converting the complex to an n-alkanoyl group. By reacting with an acid halide having the compound, a hyaluronic acid (salt) having both a hydrophobic portion and a hydrophilic portion and useful as a new material in the fields of medical products, foods, and cosmetics can be easily produced.
Claims (10)
ＣＨ３−（ＣＨ２）ｍ−ＣＯ− （２）
（式中、ｍは４〜１０の整数を表す。）。The n-alkanoylated hyaluronic acid or a salt thereof according to claim 1, wherein the n-alkanoyl group is an n-alkanoyl group represented by the following general formula (2).
CH 3 - (CH 2) m -CO- (2)
(In the formula, m represents an integer of 4 to 10.)
ＣＨ３−（ＣＨ２）ｍ−ＣＯ−Ａ （４）
（式中、ｍは３〜１５の整数であり、Ａはハロゲンを表す。）。The method for producing n-alkanoylated hyaluronic acid or a salt thereof according to claim 5, wherein the n-alkanoyl halide is an n-alkanoyl halide represented by the following general formula (4).
CH 3 - (CH 2) m -CO-A (4)
(In the formula, m is an integer of 3 to 15, and A represents halogen.)
ＣＨ３−（ＣＨ２）ｍ−ＣＯ−Ａ （５）
（式中、ｍは４〜１０の整数であり、Ａはハロゲンを表す。）。The method for producing an n-alkanoylated hyaluronic acid or a salt thereof according to claim 5, wherein the n-alkanoyl halide is an n-alkanoyl halide represented by the following general formula (5).
CH 3 - (CH 2) m -CO-A (5)
(In the formula, m is an integer of 4 to 10, and A represents halogen.)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002285769A JP4323148B2 (en) | 2002-09-30 | 2002-09-30 | n-Alkanoylated hyaluronic acid or salt thereof and process for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002285769A JP4323148B2 (en) | 2002-09-30 | 2002-09-30 | n-Alkanoylated hyaluronic acid or salt thereof and process for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004123785A true JP2004123785A (en) | 2004-04-22 |
| JP4323148B2 JP4323148B2 (en) | 2009-09-02 |
Family
ID=32278982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002285769A Expired - Fee Related JP4323148B2 (en) | 2002-09-30 | 2002-09-30 | n-Alkanoylated hyaluronic acid or salt thereof and process for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4323148B2 (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010106068A (en) * | 2008-10-28 | 2010-05-13 | Mie Prefecture | New chemical modification method for polysaccharide |
| KR101107313B1 (en) | 2009-03-06 | 2012-01-20 | 가톨릭대학교 산학협력단 | Nanoparticles formed from alkanoylated sulfate groups-containing ploysaccharides and a process for the preparation thereof |
| WO2013146376A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Coating composition and medical device |
| WO2013146380A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Coating composition and medical device |
| WO2013146381A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Drug coat layer and medical instrument including same |
| CN103505736A (en) * | 2013-09-23 | 2014-01-15 | 天津大学 | Modified hyaluronic acid based macromolecule lipidosome and preparation method thereof |
| KR20150088848A (en) * | 2012-11-27 | 2015-08-03 | 콘티프로 바이오테크 에스.알.오. | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
| JP2016518464A (en) * | 2013-03-14 | 2016-06-23 | アナコティ リミテッド | Hyaluronic acid derivative |
| WO2016135430A1 (en) * | 2015-02-27 | 2016-09-01 | Centre National De La Recherche Scientifique | Hyaluronic acid particles for cosmetic or dermatological uses |
| US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
| CN110724171A (en) * | 2019-10-24 | 2020-01-24 | 山东众山生物科技有限公司 | Preparation method of acetylated sodium hyaluronate |
| US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
| US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
| US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
| US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
| JP2020158677A (en) * | 2019-03-27 | 2020-10-01 | 国立大学法人高知大学 | Production method of ionic polymer |
-
2002
- 2002-09-30 JP JP2002285769A patent/JP4323148B2/en not_active Expired - Fee Related
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010106068A (en) * | 2008-10-28 | 2010-05-13 | Mie Prefecture | New chemical modification method for polysaccharide |
| KR101107313B1 (en) | 2009-03-06 | 2012-01-20 | 가톨릭대학교 산학협력단 | Nanoparticles formed from alkanoylated sulfate groups-containing ploysaccharides and a process for the preparation thereof |
| CN104168927A (en) * | 2012-03-27 | 2014-11-26 | 泰尔茂株式会社 | Coating composition and medical device |
| WO2013146380A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Coating composition and medical device |
| WO2013146381A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Drug coat layer and medical instrument including same |
| WO2013146376A1 (en) * | 2012-03-27 | 2013-10-03 | テルモ株式会社 | Coating composition and medical device |
| JPWO2013146376A1 (en) * | 2012-03-27 | 2015-12-10 | テルモ株式会社 | Coating composition and medical device |
| US9592322B2 (en) | 2012-03-27 | 2017-03-14 | Terumo Kabushiki Kaisha | Coating composition and medical device |
| US9999678B2 (en) | 2012-11-27 | 2018-06-19 | Contipro A.S. | C6-C18-acylated derivative of hyaluronic acid and method of preparation thereof |
| KR20150088848A (en) * | 2012-11-27 | 2015-08-03 | 콘티프로 바이오테크 에스.알.오. | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
| JP2016500130A (en) * | 2012-11-27 | 2016-01-07 | コンティプロ ビオテック スポレチノスト エス ルチェニム オメゼニム | C6-C18-acylated derivative of hyaluronic acid and process for its preparation, nanomicelle composition based on it and process for its preparation, process for preparing stabilized nanomicelle composition and use thereof |
| KR102191353B1 (en) * | 2012-11-27 | 2020-12-16 | 콘티프로 에이.에스. | C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof |
| JP2016518464A (en) * | 2013-03-14 | 2016-06-23 | アナコティ リミテッド | Hyaluronic acid derivative |
| CN103505736A (en) * | 2013-09-23 | 2014-01-15 | 天津大学 | Modified hyaluronic acid based macromolecule lipidosome and preparation method thereof |
| US10617711B2 (en) | 2014-06-30 | 2020-04-14 | Contipro A.S. | Antitumor composition based on hyaluronic acid and inorganic nanoparticles, method of preparation thereof and use thereof |
| WO2016135430A1 (en) * | 2015-02-27 | 2016-09-01 | Centre National De La Recherche Scientifique | Hyaluronic acid particles for cosmetic or dermatological uses |
| US10689464B2 (en) | 2015-03-09 | 2020-06-23 | Contipro A.S. | Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of preparation and use thereof |
| US10759878B2 (en) | 2015-06-15 | 2020-09-01 | Contipro A.S. | Method of crosslinking of polysaccharides using photoremovable protecting groups |
| US10414832B2 (en) | 2015-06-26 | 2019-09-17 | Contipro A.S | Derivatives of sulfated polysaccharides, method of preparation, modification and use thereof |
| US10618984B2 (en) | 2016-06-27 | 2020-04-14 | Contipro A.S. | Unsaturated derivatives of polysaccharides, method of preparation thereof and use thereof |
| JP2020158677A (en) * | 2019-03-27 | 2020-10-01 | 国立大学法人高知大学 | Production method of ionic polymer |
| JP7267583B2 (en) | 2019-03-27 | 2023-05-02 | 国立大学法人高知大学 | Method for producing ionic polymer |
| CN110724171A (en) * | 2019-10-24 | 2020-01-24 | 山东众山生物科技有限公司 | Preparation method of acetylated sodium hyaluronate |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4323148B2 (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4323148B2 (en) | n-Alkanoylated hyaluronic acid or salt thereof and process for producing the same | |
| Holme et al. | Chitosan N-sulfate. A water-soluble polyelectrolyte | |
| FI107050B (en) | A process for the preparation of a crosslinked acidic carboxylic polysaccharide | |
| US6673919B2 (en) | Chemically modified hyaluronic acid or salts thereof, and a process for producing thereof | |
| EP0662002B1 (en) | Alginate-bioactive agent conjugates | |
| US7521434B2 (en) | Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them | |
| Bueno et al. | N, N-Dimethyl chitosan/heparin polyelectrolyte complex vehicle for efficient heparin delivery | |
| US20190008775A1 (en) | Method for Preparing Modified Sodium Alginate Embolization Microsphere | |
| KR20040009891A (en) | Hyaluronic Acid Derivative Gel and Method for Preparing the Same | |
| JP2007153944A (en) | Cationized hyaluronic acid | |
| JP2004323453A (en) | Decomposable gel and method for producing the same | |
| EP1493754A1 (en) | Polysaccharide containing phosphorylcholine group and process for producing the same | |
| CN102260356B (en) | Chitosan derivative used as gene vector, and preparation method and application thereof | |
| JP2001505940A (en) | Novel butyrate having antiproliferative activity and pharmaceutical composition containing the same | |
| CN103483592A (en) | Polymer by grafting cyclodextrins onto polylysine and preparation method of polymer | |
| JPH0323081B2 (en) | ||
| EP0019403B1 (en) | Hydroxyalkyl-starch drug carrier | |
| Zhang et al. | Use of hydroxypropyl β-cyclodextrin as a dual functional component in xanthan hydrogel for sustained drug release and antibacterial activity | |
| JP2017520674A (en) | Method for modifying polysaccharides by grafting polyetheramine, polysaccharides modified by the method, and preparations comprising the polysaccharides and having temperature-sensitive rheological properties | |
| AU6394398A (en) | O-sulfated bacterial polysaccharides | |
| JP2006291097A (en) | Hyaluronic acid derivative and its production method | |
| CN102309761A (en) | Uncharged amphiphilic chitosan nano drug carrier and preparation method and application thereof | |
| US5472950A (en) | Compositions containing cobalt hyaluronic acid complex | |
| JP2002356501A (en) | Chemically modified hyaluronic acid or its salt and production method | |
| JP3945950B2 (en) | Edible water-absorbing polymer and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090317 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090602 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090604 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4323148 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120612 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130612 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |